<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Health and Population Sciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1BAE1842-93F0-4C9E-850D-7BD60FDF8914"><gtr:id>1BAE1842-93F0-4C9E-850D-7BD60FDF8914</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Balfe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/92EB47C3-A7C8-47C9-82FE-759E0D5DEBE0"><gtr:id>92EB47C3-A7C8-47C9-82FE-759E0D5DEBE0</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:otherNames>Alison</gtr:otherNames><gtr:surname>McKeating</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100247"><gtr:id>B9AE27A2-88DF-4633-B7F0-9192EFC86877</gtr:id><gtr:title>The role of Hepatitis C virus glycoprotein-receptor polymorphism in viral pathogenesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100247</gtr:grantReference><gtr:abstractText>Hepatitis C virus (HCV) is a globally important virus that infects 170 million individuals world wide, resulting in progressive chronic liver disease. At present, there are limited therapies available for treating hepatitis C and there is an urgent need for the development of new agents that will cure infection. Viruses initiate infection by attaching to molecules or receptors on the cell surface, providing a target for therapeutic intervention. Recent advances have identified the cellular molecules defining HCV entry into liver cells. Studies from our laboratory have shown that HCV strains differ in their interaction with host cell receptors and this will have significant consequences for virus infectivity and spread in the liver. We hypothesise that such differences in HCV-receptor interactions will influence the ?relative fitness? of a virus to transmit and infect new individuals. We will use molecular and biological methods to study transmitting HCV strains to increase our understanding of the molecular events that define and limit virus transmission.</gtr:abstractText><gtr:technicalSummary>Hepatitis C Virus (HCV) poses a global health problem, with over 170 million infected individuals worldwide at risk of developing cirrhosis and hepatocellular carcinoma. A number of anti-viral replicase molecules are in clinical development, however, drug resistance and viral genotype-specific differences will limit their efficacy, demonstrating the need for combination therapies targeting different steps of the viral replication cycle. 
Recent progress in the discovery of a strain of HCV that replicates in cell culture has enabled studies on virus assembly, release and entry, offering new targets for intervention. Studies from our laboratory have contributed to the growing understanding that HCV can disseminate via direct contacts between infected and na?ve cells. Cell-to-cell transfer of HCV is resistant to the neutralising effects of antibodies targeting the viral glycoproteins, providing a strategy for the virus to escape host immune responses. Whilst the majority of studies have focused on identifying host and viral pathways required for the genesis and release of infectious cell-free particles and inhibition of their entry into na?ve cells, cell-to-cell infection is poorly understood. We hypothesise that cell-to-cell infection is the dominant route for HCV to disseminate within the infected liver. The central aim of the current proposal is to define the mechanism(s) of cell-to-cell HCV infection and its role in virus dissemination within an infected host and transmission to new hosts in two clinical settings: recurrent HCV infection of the transplanted liver and mother to child vertical infection. Identification of the selective factors that define HCV spread and transmission will have major implications for the future treatment of HCV infection. 
At present it is not clear how HCV quasispecies are maintained during chronic infection. A dominant mode of cell-to-cell HCV spread will limit virus trafficking between sites and the resulting viruses will follow independent evolutionary histories, i.e. become compartmentalised. Classic genetic models predict that evolution will occur more rapidly in a series of small isolated populations than in a single homogeneous pool. We propose to study the quasispecies structure of the HCV infected liver. This information will have a major impact on our understanding of HCV pathogenesis and the mechanism(s) underlying virus escape from host immune responses and anti-viral therapies.</gtr:technicalSummary><gtr:fund><gtr:end>2017-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1248522</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>To study the role of glucocorticoid signaling in the hepatitis B and C virus lifecycle.</gtr:description><gtr:id>BDD7DF8F-C769-4677-AAE1-7699BAD6AA10</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545a5a704465c8.68294022-1</gtr:outcomeId><gtr:partnerContribution>To study the role of glucocorticoid signaling in the hepatitis B and C virus lifecycle.</gtr:partnerContribution><gtr:piContribution>David Ray - Institute for Human Development, University of Manchester</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>David Adams - To study hepatitis C virus pathogenesis</gtr:description><gtr:id>E34D134F-4403-4DD6-9717-3A4D5EFD2A9D</gtr:id><gtr:impact>Stamataki, Z., Tilakaratne, S., Adams, D.H., and McKeating, J.A. (2011). Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. PLoS One 6(9):e25789.

Rowe, I.A., Wilson, G.K., Galsinh, S.K., Durrant, S., Lazar, C., Branza-Nichita, N., Bicknell, R., Adams, D.H., Balfe,P., and McKeating, J.A. (2013). Paracrine signals from liver sinusoidal endothelium regulate HCV replication. Hepatology, in press.

Fletcher, N.F., Sutaria, R., Juandy, J., Barnes, A., Blahova, M., Hu, K., Cosset, F-L., Balfe, P., Adams, D.H., Curbishley, S,M., Bertoletti, A. and McKeating, J.A. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology, in press.

Stamataki, Z., Shannon-Lowe, C., Shaw, J., Mutimer, D., Rickinson, A. B., Gordon, J., Adams, D. H., Balfe, P. &amp;amp; McKeating, J. A. (2009). Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood 113, 585-593.

Reynolds, G. M., Harris, H. J., Jennings, A., Hu, K., Grove, J., Lalor, P. F., Adams, D. H., Balfe, P., Hubscher, S. G. &amp;amp; McKeating, J. A. (2008). Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 47, 418-427.

Lai, W. K., Curbishley, S. M., Goddard, S., Alabraba, E., Shaw, J., Youster, J., McKeating, J. A &amp;amp; Adams, D. H. (2007). Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J Hepatology 47, 338-347.

Grants: 
Liver Biomedical Research Unit to study Immune and cell therapy of liver disease. Investigators: Adams, McKeating, Newsome, Stewart, Johnson, Young. Awarding Body: National Institute of Health Research (UK). Funds: &amp;pound;6.35 million. Dates: 2012-2017.</gtr:impact><gtr:outcomeId>kvDZ4YBt82L-1</gtr:outcomeId><gtr:partnerContribution>Immunological expertise</gtr:partnerContribution><gtr:piContribution>Viral hepatitis Expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Antonio Bertoletti - To study the role of immune cells in hepatitis C entry and infection</gtr:description><gtr:id>7C9E0662-9BDE-4A32-8275-8E01440872A0</gtr:id><gtr:impact>Fletcher, N.F., Sutaria, R., Juandy, J., Barnes, A., Blahova, M., Hu, K., Cosset, F-L., Balfe, P., Adams, D.H., Curbishley, S,M., Bertoletti, A. and McKeating, J.A. Activated macrophages promote hepatitis C virus entry in a tutor necrosis factor-dependent manner. Hepatology. 59: 1320-30, 2014.</gtr:impact><gtr:outcomeId>N8vrpG3Av7R-1</gtr:outcomeId><gtr:partnerContribution>Provide immunological expertise and access to liver perfusate.</gtr:partnerContribution><gtr:piContribution>Provide viral hepatitis expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Thomas Baumert - To study the mechanism of hepatitis C virus entry into polarized hepatocytes.</gtr:description><gtr:id>B27D4186-28C6-4D38-AA00-CDDD4CE11DD4</gtr:id><gtr:impact>Zona, L., Lupberger, J., Thumann, C., Ahmed-Adrar, N.S., Thumann, C., Harris, H.J., Barnes, A., Florentin, J., Taware, R.G., Xiao, F., Turek, M., Durand, S.C., Duong, F.H., Heim, M.H., Cosset, F-L., Hirsch, I., Brino, L., Zeisel, M.B., Le Naour, F., McKeating, J.A. and Baumert, T.F. (2013). HRas signal transduction mediates hepatitis C virus entry by triggering the assembly of the host tetraspanin receptor complex. Host Cell and Microb 13: 302-13.
Fofana, I., Zona, L., Thumann, C., Heydmann, L., Durand, S.C., Lupberger, J., Blum, H.E., Pessaux, P, Gondeau, C., Reynolds, G.M., McKeating, J.A., Grunert, F., Thompson, J., Zeisel, M.B., and Baumert, T.F. Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes using monoclonal antibodies. J Virol, in press.
Farquhar, M. J., Hu, K., Harris, H.J., Davis, C., Brimacombe, C.L., Baumert, T.F., Rappoport, J.Z., Balfe, P., and McKeating, J.A. (2012). Hepatitis C virus promotes CD81 and claudin-1 endocytosis. J Virology 86: 4305-16.
Fletcher, N.F., Wilson, G.K., Murray, J., Hu, K., Lewis, A., Reynolds, G., Stamataki, Z., Meredith, L.W., Rowe, I.A., Luo, G., Lopez-Ramirez, M.A., Baumert, T. F., Weksler, B., Couraud, P.O., Kim, S.K., Romero, I.A., Jopling, C., Morgello, S., Balfe, P., and McKeating, J.A. (2012). Hepatitis C virus infection of blood brain barrier endothelial cells. Gastroenterology 142: 634-643.
Lupberger, J., Zeisel, M.B., Xiao, F., Thumann, C., Fofana, I., Zona, L., Davis, C., Mee, C.J., Turek, M., Gorke, S., Royer, C., Fischer, B., Zahid, M.N., Lavillette, D., Fresquet, J., Cosset, F-L., Rothenberg, S.M., Pietschmann, T., Patel, A.H., Pessaux, P., Doffeol, M., Raffelsberger, W., Poch, O., McKeating, J.A., Brino, L., and Baumert, T.F. (2011). EGF receptor and EphA2 are hepatitis C virus host entry factors and targets for antiviral therapy. Nat Med, 17: 589-95.
Syder, A.J, Lee, H., Zeisel, M.B., Grove, J., Soulier, E., Macdonald, J., Chow, S., Chang, J., Baumert, T.F., McKeating, J.A., McKelvy, J., Wong-Staal, F. (2011). Small molecule scavenger receptor B1 antagonists are potent HCV entry Inhibitors. J. Hepatology, 54, 48-55.
Brimacombe, C., Grove, J., Meredith, L., Hu, K., Syder, A.J., Flores, M.F., Timpe, J., Krieger, S.E., Baumert, T.F., Tellinghuisen, T.L., Wong-Staal, F., Balfe, P., and McKeating, J.A. (2011). Neutralizing antibody resistant hepatitis C virus cell-to-cell transmission. J.Virology, 85, 596-605. 
Fletcher, N.F., Yang, J.P., Farquahr, M.F., Hu, K., Davis, C., He, Q., Dowd, K., Ray, S.C., Krieger, S.E., Baumert, T.F., Balfe, P., Wong-Staal, F., and McKeating, J.A. (2010). Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology, 139: 1365-1374.
Fofana, I., Krieger, S.E., Grunert, F., Glauben, S., Xiao, F., Fafi-Kremer, S., Soulier, E., Royer, C., Mee, C.J., McKeating J.A., Dragic, T., Schuster, C., Thompson, J., and Baumert, T.F. (2010). Monoclonal anti-Claudin 1 antibodies for the prevention of hepatitis C virus infection. Gastroenterology, 139:953-64.
Krieger, S.E., Zeisel, M.B, Davis, C., Thumann, C., Harris, H.J., Schnober, E.K., Mee, C.J., Soulier, E., Lambotin, M., Grunert, F., Loan Dao Thi, V., Dreux, M., Cosset, F-L., McKeating, J.A., Schuster, C., and Baumert, T.F (2010). Inhibition of hepatitis C virus infection by anti Claudin antibodies is mediated by neutralization of E2-CD81-Claudin 1 association(s). Hepatology, 51:1144-57.
Kapadia, S. B., Barth, H., Baumert, T., McKeating, J. A. &amp;amp; Chisari, F. V. (2007). Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virology 81, 374-383.</gtr:impact><gtr:outcomeId>egXQirWTpMc-1</gtr:outcomeId><gtr:partnerContribution>Complementary viral expertise.</gtr:partnerContribution><gtr:piContribution>Provide imaging expertise of viral receptor trafficking.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Munich</gtr:collaboratingOrganisation><gtr:department>Institute of Virology</gtr:department><gtr:description>Ulla Protzer - Mechanism of hepatitis B virus entry.</gtr:description><gtr:id>FE991AB9-0163-40C1-8B21-5F93C0FCB899</gtr:id><gtr:impact>'Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors.' &amp;nbsp;Meredith LW, Hu K, Cheng X, Howard CR, Baumert TF, Balfe P, van de Graaf KF, Protzer U, McKeating JA,&amp;nbsp;J Gen Virol, 97: 121-7, 2016.</gtr:impact><gtr:outcomeId>545a5c127f87f9.87225376-1</gtr:outcomeId><gtr:partnerContribution>Mechanism of hepatitis B virus entry.</gtr:partnerContribution><gtr:piContribution>Ulrike Protzer - Institute of Virology, University of Munich, Germany. Mechanism of hepatitis B virus entry.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The role of HIFs in hepatitis B virus infection</gtr:description><gtr:id>184185E1-A92A-4F8E-8979-9E10423E008A</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545a5c702598f4.87732609-1</gtr:outcomeId><gtr:partnerContribution>The role of HIFs in hepatitis B virus infection</gtr:partnerContribution><gtr:piContribution>Mala Maini - UCL, London.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>To study the role of circadian clocks in HIV infection.</gtr:description><gtr:id>5FB90F89-4481-44FA-91FB-513F166D6494</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545a5af4093aa7.61221576-1</gtr:outcomeId><gtr:partnerContribution>To study the role of circadian clocks in HIV infection.</gtr:partnerContribution><gtr:piContribution>Andrew Loudon - Institute for Human Development,</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Ellie Barnes - To study the role of neutralizing antibodies in hepatitis C virus infection.</gtr:description><gtr:id>D1680D23-D360-4CA3-B0FC-3282AE5C59F1</gtr:id><gtr:impact>Stratified Medicine to Optimise the Treatment of Patients with Hepatitis C Virus Infection (STOP-HCV). Investigators: Consortium of UK investigators, led by Ellie Barnes (Oxford University). Awarding body: MRC. Funds: &amp;pound;6.3M. Dates: 01/5/13 - 31/4/18.</gtr:impact><gtr:outcomeId>cb2PJoZBT1N-1</gtr:outcomeId><gtr:partnerContribution>Immunology expertise</gtr:partnerContribution><gtr:piContribution>Viral hepatitis expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Babraham Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The role of autotaxin-lysophosphatidic acid receptor signaling in hepatitis B and C virus replication.</gtr:description><gtr:id>2A035712-34DB-420F-810E-1C02BDBAE739</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545a5b73b7c4f4.51238421-1</gtr:outcomeId><gtr:partnerContribution>The role of autotaxin-lysophosphatidic acid receptor signaling in hepatitis B and C virus replication.</gtr:partnerContribution><gtr:piContribution>The role of autotaxin-lysophosphatidic acid receptor signaling in hepatitis B and C virus replication.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Research Seminar, King's College London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D8200337-01E0-46F6-AA1D-A4F35CF4AD7B</gtr:id><gtr:impact>Invited research Seminar</gtr:impact><gtr:outcomeId>58c648c2ba9495.83334161</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Flak International Meeting, basic science to clinical practice</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B7DF67E2-FAA2-4D2D-AD67-0C256C173E16</gtr:id><gtr:impact>Plenary session at policy forum</gtr:impact><gtr:outcomeId>58c647faaee9a7.18377029</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Big Bang Fair</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C474AB20-31B6-4CA2-BC49-D79572DAC2CB</gtr:id><gtr:impact>Ran activity at the &amp;quot;Big Bang Fair&amp;quot; - a national science fair at the Birmingham NEC targeted to School years 7 - 11 with &amp;gt; 15,000 attendees.
Also acted as Judge for national science scheme entries.</gtr:impact><gtr:outcomeId>56dc649c6281b3.75655789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STEMnet ambassador scheme</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>45C7C9F2-7A4D-4F1F-805A-C5B2302BECBA</gtr:id><gtr:impact>&amp;gt;20 ambassadors from MDS are now actvively engaged in visits to West Midlands Schools and MDS has become the largest group at UoB to send people out on these visits. In the last year 45 visits were made and we estimate &amp;gt;1,000 children (and their teachers) were visited.

Several of our ambassadors are visiting schools for the third year running and the schools appreciate the presence of UoB in their community</gtr:impact><gtr:outcomeId>s5J9nVTQroN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits and lectures</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F1A0134B-8CA2-47FC-B5D7-BE7D76BD3089</gtr:id><gtr:impact>Virology talks to 6th form students, with description of research career and role of women in science.

Teachers reported that several students chose to study Biology or Medicine as a result of these talks (indeed one of these students is now on our course in Birmingham).</gtr:impact><gtr:outcomeId>E3C3AD3768C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HepCar Kick off meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6B0DDE36-5029-4409-B799-087823B6B04B</gtr:id><gtr:impact>Address to Meeting, chair of Research committee</gtr:impact><gtr:outcomeId>58c646797a3507.36822757</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, Institute Pasteur</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6EC4C5F7-7701-4C63-8C63-F595CB70AA3E</gtr:id><gtr:impact>Invited speaker</gtr:impact><gtr:outcomeId>58c6484a3242c3.99171297</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F1160AF4-F7B1-413B-90CB-2E471FCA396A</gtr:id><gtr:impact>Plenary speaker at Conference</gtr:impact><gtr:outcomeId>58c645fbc43461.22957529</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Careers fairs</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B6112F49-5880-44B2-BA9D-1BDF14FCDD46</gtr:id><gtr:impact>Had several students apply to UoB on the basis of our presentations. To date these careers talks have been give to over 500 17-18 year olds

Repeat visits invitations from all schools involved. several work experience students have applied for time in our department on the basis of these activities.</gtr:impact><gtr:outcomeId>mMbrF7GoAtN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School science weeks</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7CBCFB18-2F4D-4B29-9E09-E633844AF666</gtr:id><gtr:impact>Series of hands on experience of microbiology for primary school children.

School reports improved KS2 results and better understanding of health among children</gtr:impact><gtr:outcomeId>10DD0C07164</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, Freiburg</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C0A18E1-A6BA-4D19-8A5E-BA7408AE4DD8</gtr:id><gtr:impact>Research seminar and collaborative meeting</gtr:impact><gtr:outcomeId>58c646d6120027.84249718</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School prize giving &amp; lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A8983CBF-BD5F-4BDC-A0DD-45044410A6D8</gtr:id><gtr:impact>Gave talk on women in science, careers and research. Presented School prizes

School reported strengthening of science curriculum</gtr:impact><gtr:outcomeId>79A558E6AB0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PathCo Meeting, Sienna</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>80D5041B-487B-4D06-9B80-AABA921F0B0E</gtr:id><gtr:impact>Chair of Scientific session and presenter</gtr:impact><gtr:outcomeId>58c64731269821.92761286</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, WIMM, Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E3ADD922-5737-4A57-AFC3-1ED85C83B4BA</gtr:id><gtr:impact>Research Seminar</gtr:impact><gtr:outcomeId>58c6488548d115.25385341</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, IAS, TUM, Munich</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>35A5B962-AF1C-42D5-AF32-CFD0ABA795FB</gtr:id><gtr:impact>Research seminar</gtr:impact><gtr:outcomeId>58c6479a463c71.41528492</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pint of Science lectures</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B36055D6-633A-4B4D-ABCB-C6261061342E</gtr:id><gtr:impact>Pint of Science is an international initiative to enhance public understanding of science. We took part in the inaugural series in Birmingham in 2015.</gtr:impact><gtr:outcomeId>56dc63d8ed3de5.43517943</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>761914</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Framework 7 Collaborative Funding Scheme</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>D6425E9D-9494-4C2D-BD1F-865C3815D46C</gtr:id><gtr:outcomeId>56cde2428c15f1.28203769</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>242000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Fellowship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>200113/Z/15/Z</gtr:fundingRef><gtr:id>3976A653-688C-494E-AF3B-F1F1C2C96FB7</gtr:id><gtr:outcomeId>58c649888ab7c3.41269656</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>154840</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie Fellowship (Recoin)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>58EFF716-870B-4D0D-9935-AA1CBA1BD3C9</gtr:id><gtr:outcomeId>FEjDNyZKyyn</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>241807</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>200113/Z/15/Z</gtr:fundingRef><gtr:id>668C93EB-9453-4416-B0E1-9A3A35A99D88</gtr:id><gtr:outcomeId>56dc669f519e02.80901738</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>85000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>012C544E-3B08-4CDE-B876-D511F8302BC9</gtr:id><gtr:outcomeId>56dc670106b268.53381853</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clarendon Scholarship</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>F9716E51-B6B4-4029-98FB-81BB2B8AFC6F</gtr:id><gtr:outcomeId>58c64a8fed6787.24082603</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>390000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>BBSRC Impact Award</gtr:department><gtr:description>Research grant</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/N008553/1</gtr:fundingRef><gtr:id>10F4864B-4E4E-4A9F-AFD5-514F69BC969E</gtr:id><gtr:outcomeId>56dc660b41ced3.05575103</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>219640</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Research Fellowship</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DCE2E81E-8DE0-4224-A34C-46934630FE5B</gtr:id><gtr:outcomeId>56cde038e31bb6.08553476</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>299200</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D7C36F3A-464F-4987-9C0B-9FDC89C5798C</gtr:id><gtr:outcomeId>56cde0cb87e429.06356976</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>148424</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie Fellowship (AKAP)</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>C37FD1A9-B47A-4AA7-8772-9AC6E8A4D01C</gtr:id><gtr:outcomeId>XggxpfjwjGU</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1253354</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Research Grant (FP7 PathCo)</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>5E2554ED-6D5F-4DDA-AB86-EEAA24CE0CB9</gtr:id><gtr:outcomeId>MRwaN7aACsr</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>247000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>TUM Fellowship scheme</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Technical University of Munich</gtr:fundingOrg><gtr:id>BE46DF5C-82D8-4344-B581-1516AD5231F7</gtr:id><gtr:outcomeId>56cde367162c60.04472991</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2022-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>0F34FE5A-1726-43CC-A296-78ABB8B1A320</gtr:id><gtr:outcomeId>58c64a2bc1e025.72988672</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F3AC9F2C-AECD-4B37-9896-D31B61A46901</gtr:id><gtr:title>The past, present and future of neutralizing antibodies for hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd35d1b54c6b5cb7a796ed9ffb36be05"><gtr:id>cd35d1b54c6b5cb7a796ed9ffb36be05</gtr:id><gtr:otherNames>Ball JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>54593751dacb08.84135813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77ABD15E-8F41-49B1-9DAE-926DB531937A</gtr:id><gtr:title>A role for CD81 and hepatitis C virus in hepatoma mobility.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55308829b0f2e78b8deb7e8dbd9a471c"><gtr:id>55308829b0f2e78b8deb7e8dbd9a471c</gtr:id><gtr:otherNames>Brimacombe CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>545937523aa714.94986106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3F624E8-E466-43A9-8974-6D364077FAD4</gtr:id><gtr:title>Early infection events highlight the limited transmissibility of hepatitis C virus in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_15282_22_23353869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F1E630F-C644-4422-8B94-B5B464E7D54F</gtr:id><gtr:title>Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55308829b0f2e78b8deb7e8dbd9a471c"><gtr:id>55308829b0f2e78b8deb7e8dbd9a471c</gtr:id><gtr:otherNames>Brimacombe CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>kizQrUy44Lu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40877F58-8305-4352-B6C3-C75DA8B74687</gtr:id><gtr:title>High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc69287aca943f9da74db554607d91d4"><gtr:id>fc69287aca943f9da74db554607d91d4</gtr:id><gtr:otherNames>Hedegaard DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a35e34038a321.50887883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27A14716-5463-4028-9115-807AAADEC63C</gtr:id><gtr:title>Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_540e13ce13c1bc11e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51020186-E617-4058-A91F-F270D48931CD</gtr:id><gtr:title>Structural characterization of CD81-Claudin-1 hepatitis C virus receptor complexes.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47a7e0c1a30cbdc3c9114d7bc4876109"><gtr:id>47a7e0c1a30cbdc3c9114d7bc4876109</gtr:id><gtr:otherNames>Bonander N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_15282_22_21428935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F4922A1-07AC-4362-BA16-EE640584EF16</gtr:id><gtr:title>Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffb3d69db62b4506befe77f9713c06f7"><gtr:id>ffb3d69db62b4506befe77f9713c06f7</gtr:id><gtr:otherNames>Mathiesen CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5675e4eb8b58c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A788AAFD-AF24-441E-AF99-A8B4BEDB97BC</gtr:id><gtr:title>Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>pm_15282_22_24157306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95DB45CC-F33F-4181-8520-CA2B7B30E04A</gtr:id><gtr:title>In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface.</gtr:title><gtr:parentPublicationTitle>Cellular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7db0f8aa3dff74a26cb87933de072153"><gtr:id>7db0f8aa3dff74a26cb87933de072153</gtr:id><gtr:otherNames>Davis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-5814</gtr:issn><gtr:outcomeId>pm_15282_22_22897233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D40D252-DF39-4A88-8D7C-64CA118072CF</gtr:id><gtr:title>A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81.</gtr:title><gtr:parentPublicationTitle>Wellcome open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe40ce492da64d8686da83c7038b7e65"><gtr:id>fe40ce492da64d8686da83c7038b7e65</gtr:id><gtr:otherNames>Grove J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2398-502X</gtr:issn><gtr:outcomeId>5a2fd686ab7d17.93512529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9415B14-E703-4217-9F0F-43811479948F</gtr:id><gtr:title>Hepatitis C virus entry: beyond receptors.</gtr:title><gtr:parentPublicationTitle>Reviews in medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1052-9276</gtr:issn><gtr:outcomeId>pm_15282_22_22392805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99F25FE1-84AC-4F6B-AC95-B0CB3A3BD213</gtr:id><gtr:title>Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>56cddd210c5370.98820982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>100C11EF-A1E8-4922-A60D-C756FA9BB224</gtr:id><gtr:title>A dual role for hypoxia inducible factor-1a in the hepatitis C virus lifecycle and hepatoma migration.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a7463d1f8fa86587b5c95fd20445a75"><gtr:id>1a7463d1f8fa86587b5c95fd20445a75</gtr:id><gtr:otherNames>Wilson GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_15282_22_22178269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24A11790-8471-4C3D-A3EC-701302B85A08</gtr:id><gtr:title>Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>56cddd20d4a5d7.19537286</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98BF6A0D-6F89-4DBE-A198-88962275E91C</gtr:id><gtr:title>Glucocorticoids promote Von Hippel Lindau degradation and Hif-1a stabilization.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/360bbf1bba69620adc324a2fd79bb87e"><gtr:id>360bbf1bba69620adc324a2fd79bb87e</gtr:id><gtr:otherNames>Vettori A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5a35e3de6f42d2.00177482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5698E7BC-9898-4F41-8015-0F1749951264</gtr:id><gtr:title>Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fba3ccb5d5fdeb9fdfc12cfe1fdc3142"><gtr:id>fba3ccb5d5fdeb9fdfc12cfe1fdc3142</gtr:id><gtr:otherNames>Tarr AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_22_22171278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2792D251-E0FA-48D0-94B2-17B184BC2514</gtr:id><gtr:title>Hepatitis C virus and the brain.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>pm_15282_22_22497808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B3E6588-99D5-414E-89CE-BA6C23B4B8B4</gtr:id><gtr:title>Editorial overview - virus entry: towards reality - refining models of virus entry.</gtr:title><gtr:parentPublicationTitle>Current opinion in virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/767df1a9232354feb7b48f3aca089c0a"><gtr:id>767df1a9232354feb7b48f3aca089c0a</gtr:id><gtr:otherNames>Marsh M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1879-6257</gtr:issn><gtr:outcomeId>54593751b27af0.67394948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF662310-BA52-46CB-8F3A-DFF605225F93</gtr:id><gtr:title>Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58b555856aed16.73568455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0174A869-2154-472F-8A7E-A88DC38C407E</gtr:id><gtr:title>Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e5bc1756e96e835a0772ea0b6c44eaa"><gtr:id>3e5bc1756e96e835a0772ea0b6c44eaa</gtr:id><gtr:otherNames>Brown RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_22_22855498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>075448B1-7341-430C-AD50-3B0A709728EF</gtr:id><gtr:title>Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39fa156771b11e594ede29bd67666cdf"><gtr:id>39fa156771b11e594ede29bd67666cdf</gtr:id><gtr:otherNames>Mailly L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>56cddd213f3151.63104440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A5C7341-933F-491E-8AD7-E063134978D0</gtr:id><gtr:title>Hepatitis C virus entry and the tetraspanin CD81.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_15282_22_21428934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A3D9482-8812-4AD7-9846-8AC1A3B1E33F</gtr:id><gtr:title>IFITM1 is a tight junction protein that inhibits hepatitis C virus entry.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cabb205093b1d3a66cbb38c64024ddca"><gtr:id>cabb205093b1d3a66cbb38c64024ddca</gtr:id><gtr:otherNames>Wilkins C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15282_22_22996292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C706087-C7DB-472C-9728-45BF1AACC2DA</gtr:id><gtr:title>Hepatitis C virus induces CD81 and claudin-1 endocytosis.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_22_22318146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8BE903B-A9D5-4F82-B695-45FCDD44A602</gtr:id><gtr:title>Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a7463d1f8fa86587b5c95fd20445a75"><gtr:id>1a7463d1f8fa86587b5c95fd20445a75</gtr:id><gtr:otherNames>Wilson GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>5675df95d1db2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FC2E5DB-4D68-4452-A7B5-0605B6755EFD</gtr:id><gtr:title>Hepatoma polarization limits CD81 and hepatitis C virus dynamics.</gtr:title><gtr:parentPublicationTitle>Cellular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c9d36662cb20471af6a26537b90de2"><gtr:id>72c9d36662cb20471af6a26537b90de2</gtr:id><gtr:otherNames>Harris HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1462-5814</gtr:issn><gtr:outcomeId>pm_15282_22_23126643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80869DD0-E959-429E-BDD2-4AB789DDD841</gtr:id><gtr:title>TNF superfamily members promote hepatitis C virus entry via an NF-?B and myosin light chain kinase dependent pathway.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>58b5554e6fcf35.78693952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A53F678E-B8BC-4945-9406-FC89FA341546</gtr:id><gtr:title>Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a7463d1f8fa86587b5c95fd20445a75"><gtr:id>1a7463d1f8fa86587b5c95fd20445a75</gtr:id><gtr:otherNames>Wilson GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>545937528d8546.70767065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>434F5C9D-6E7B-470C-8461-77166B70BBF6</gtr:id><gtr:title>HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86ff923ea25b951c739188c377e6136c"><gtr:id>86ff923ea25b951c739188c377e6136c</gtr:id><gtr:otherNames>Zona L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>pm_15282_22_23498955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67EEA750-CC5E-4E20-B742-6DA47C526377</gtr:id><gtr:title>Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2b4f6fdb72f1cdaef37b28a889ce1e7"><gtr:id>d2b4f6fdb72f1cdaef37b28a889ce1e7</gtr:id><gtr:otherNames>Desombere I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56cddd20a29a86.18706153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAFFE3D9-5602-44A1-81DA-D93FFD3EA9EC</gtr:id><gtr:title>Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15282_22_23775568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17788701-30A1-4F30-ADD1-863446EAE472</gtr:id><gtr:title>An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fba3ccb5d5fdeb9fdfc12cfe1fdc3142"><gtr:id>fba3ccb5d5fdeb9fdfc12cfe1fdc3142</gtr:id><gtr:otherNames>Tarr AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15282_22_23553604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D2D1FDC-3EEB-4F96-AD7C-192723150A40</gtr:id><gtr:title>Deep sequencing of hepatitis C virus reveals genetic compartmentalization in cerebrospinal fluid from cognitively impaired patients.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d84a8ec626304bd46399f5c70de06714"><gtr:id>d84a8ec626304bd46399f5c70de06714</gtr:id><gtr:otherNames>Tully DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>58b5554e40ef86.09171928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C3E6D48-85EF-44F2-98F5-F50282A143A6</gtr:id><gtr:title>Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fcb460d7dd55791392aef8b45f0f577"><gtr:id>0fcb460d7dd55791392aef8b45f0f577</gtr:id><gtr:otherNames>Chmielewska AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>54593752142731.72826452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5042FD2-252A-4CC9-8E5B-D01DAA8EF926</gtr:id><gtr:title>Type I interferon rapidly restricts infectious hepatitis C virus particle genesis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>54593752635ac0.16616216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E20D27F8-2B28-457E-993A-4D9196C8168B</gtr:id><gtr:title>Hepatitis C virus infection of cholangiocarcinoma cell lines.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>5675dff8c1e5c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7883123-B84D-462C-BFA7-D6C906897279</gtr:id><gtr:title>Hepatitis C virus infects the endothelial cells of the blood-brain barrier.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_15282_22_22138189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57C57F1F-01AB-45F8-8C71-7FBD4DBA90E1</gtr:id><gtr:title>Entry of hepatitis B and C viruses - recent progress and future impact.</gtr:title><gtr:parentPublicationTitle>Current opinion in virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/363ad5d61c060939ed60a0c5465c493f"><gtr:id>363ad5d61c060939ed60a0c5465c493f</gtr:id><gtr:otherNames>Baumert TF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1879-6257</gtr:issn><gtr:outcomeId>54593751897c65.47800284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A418ABF-8466-42E3-BBBE-C5851CE56177</gtr:id><gtr:title>Production, purification and characterization of recombinant, full-length human claudin-1.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47a7e0c1a30cbdc3c9114d7bc4876109"><gtr:id>47a7e0c1a30cbdc3c9114d7bc4876109</gtr:id><gtr:otherNames>Bonander N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15282_22_23704991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05A8EFDB-2C8D-4AB3-AF37-4A903455D4F5</gtr:id><gtr:title>Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5bded635fcd0ab8d05007017a49ea62"><gtr:id>a5bded635fcd0ab8d05007017a49ea62</gtr:id><gtr:otherNames>Fofana I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_22_23864633</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100247</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>